Scorpion Therapeutics

Scorpion Therapeutics

Edit info

  • Founded: 2020
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Brain cancers
  • Drug types: ONC
  • Lead product: STX-478
  • Funding: $162M B Jan 2021; $108M A Oct 2020
  • Investors: tlas Venture, Omega Funds, Vida Ventures, Abingworth, Partners HealthCare Innovation


scorpiontx.com

linkedin.com

job board


Business:

Small Molecules

Drug notes:

STX-721 Clin0 NSCLC; STX-241 Clin0 NSCLC; 3 add'l RD programs

About:

Scorpion Therapeutics is expanding the potential of precision medicine to cancer patients. Using their fully integrated discovery platform that uses cancer biology, medicinal chemistry, chemical proteomics and molecular biophysics, Scorpion is advancing drug discovery, small molecule design and target identification to rapidly create selective small molecule compounds against an unprecedented spectrum of targets. Scorpion is currently focusing on validated oncogene targets as well as undruggable targets and novel cancer targets. Their lead program, STX-478, is an oral inhibitor of PI3K-alpha that is in clinical stages as a monotherapy for patients with breast cancer.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com